//
Twelve or 30 months of dual antiplatelet therapy after drug-eluting stents
A randomized comparison of Coronary Stents according to Short or Prolonged durations of Dual Antiplatelet Therapy in patients with Acute Coronary Syndromes: a pre-specified analysis of the SMART-DATE trial
The optimal duration of dual antiplatelet therapy after coronary stent implantation: to go too far is as bad as to fall short
Ticagrelor with or without Aspirin in High-Risk Patients after PCI
A risk score to predict postdischarge bleeding among acute coronary syndrome patients undergoing percutaneous coronary intervention: BRIC-ACS study
Primary Results of the EVOLVE Short DAPT Study: Evaluation of 3-Month Dual Antiplatelet Therapy in High Bleeding Risk Patients Treated With a Bioabsorbable Polymer-Coated Everolimus-Eluting Stent
Safety and efficacy of the bioabsorbable polymer everolimus-eluting stent versus durable polymer drug-eluting stents in high-risk patients undergoing PCI: TWILIGHT-SYNERGY
Efficacy and Safety of Ticagrelor Monotherapy in Patients Undergoing Multivessel PCI